Phase 2 Breast Cancer Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women who have gone through menopause (as defined by NCCN guidelines), are aged 18 or older, and have estrogen receptor-positive (ER+) breast cancer that has spread to other parts of the body or has come back locally in a way that cannot be treated with a goal of cure.
- People whose cancer has previously been treated with a specific type of drug called a CDK4/6 inhibitor (specifically palbociclib, ribociclib, or abemaciclib), either on its own or combined with a hormone-based therapy, for advanced disease.
- People who have had up to 3 lines of treatment after their CDK4/6 inhibitor, any number of prior hormone-based treatments, and up to 1 prior chemotherapy course.
- People whose cancer has been confirmed as ER+ through a tissue sample (biopsy) taken from a site of advanced or returning disease — with some exceptions for people with bone-dominant cancer or cases where a safe biopsy cannot easily be obtained, where the original cancer diagnosis may be used instead.
- People whose cancer tests positive for estrogen receptors in at least 1% of cancer cells on a standard lab test.
- People whose cancer is confirmed to not have high levels of a protein called HER2 (based on standard laboratory testing methods).
- People whose tumor or blood sample has been tested for specific genetic changes in a certified laboratory after their cancer stopped responding to a CDK4/6 inhibitor — or people who are willing to have this testing done as part of the study.
- People who have stored (archived) tumor tissue available that can be used for research, ideally enough to produce at least 10 thin tissue sections.
- People who have had standard imaging scans to assess the extent of their cancer (such as a PET/CT scan, or a CT scan with contrast plus a bone scan).
- People who are willing and able to give written informed consent to take part in the study.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose most recent or current treatment includes abemaciclib.
- People who are currently receiving other cancer treatments, with the exception of bone-strengthening medications such as bisphosphonates or denosumab.
- People who have taken part in another experimental cancer treatment study within the past 3 weeks.
- People who have a known brain or central nervous system involvement from their cancer that has not been treated, unless it has been clinically stable for at least 3 months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mary Chamberlin, MD, Dartmouth-Hitchcock Medical Center
Phone: 603-650-5021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of clinical benefit within each arm in patients previously treated with a CDK4/6 inhibitor.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.